William Greenlee, PhD
William J. Greenlee, PhD, received his bachelor’s degree in chemistry from The Ohio State University, Columbus, OH, and his doctorate from Harvard University, Cambridge, Mass. He was a National Institutes of Health postdoctoral fellow at Columbia University, New York, before joining Merck Research Laboratories, Rahway, NJ.
At Merck, Dr. Greenlee was a member of the team that discovered Merck’s antihypertensive drugs Vasotec® and Prinivil®. His group worked on other cardiovascular programs, including angiotensin II antagonists and endothelin antagonists. He was promoted to Director in 1989 and to Senior Director in 1992.
In 1995, Dr. Greenlee joined Schering-Plough as Senior Director, Cardiovascular and CNS Chemical Research and was promoted to Vice President in 2002. During 15 years at Schering-Plough, he and his group advanced 11 drug candidates into clinical trials. Following the acquisition of Schering-Plough by Merck in 2009, he served as Chemistry Site Head in Kenilworth, NJ, until August, 2010. He is now an independent medicinal chemistry consultant.
Dr. Greenlee has made numerous contributions of his time and talents to the American Chemical Society (ACS) and other professional organizations. He served as chair and program chair for the Medicinal Chemistry and Organic Chemistry Divisions of ACS and was organizer for the 43rd National Organic Chemistry Symposium in 2012. He is Perspectives Editor for the Journal of Medicinal Chemistry and serves on the Editorial Advisory Board for ACS Medicinal Chemistry Letters. Dr. Greenlee has been Co-Organizer of the annual Drew University Residential School on Medicinal Chemistry since 2002.
Dr. Greenlee received the Alfred Burger Award in Medicinal Chemistry from the ACS in 2004 and was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006. He was elected a Fellow of the American Association for the Advancement of Science in 2007 and a Fellow of the ACS in 2009. He is coauthor of more than 200 research publications and co-holder of more than 75 U.S. patents.